Clinical trials: Vorinostat
Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab and combination chemotherapy and to see how well it works in treating patients with newly diagnosed stage II, stage…
- Conditions
- Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Trial name
- NCT00972478
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 190 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Alzheimer Disease
Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease
This Clinical Trial is an open, non-randomized Phase Ib study to determine the maximal tolerable dose (MTD) of Vorinostat in Alzheimer disease (AD) patients between (including) 55 and 90 years with mild symptoms.
- Trial name
- VostatAD01 (NCT03056495)
- Testing
- N-hydroxy-N'-phenyl-octanediamide (Vorinostat)
- Where
- 2 sites in Germany
- Volunteers
- 9 people
- Sponsor
- German Center for Neurodegenerative Diseases (DZNE)
Neuroblastoma
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard…
- Trial name
- PEDS-PLAN (NCT02559778)
- Testing
- Ceritinib, dasatinib, sorafenib
- Where
- 28 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Giselle Sholler
Pitt Hopkins Syndrome
An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome
The study is an exploratory evaluation of the safety and efficacy of vorinostat in Pitt Hopkins syndrome. Each patient will be self-controlled in an adapted N-of-1 study design methodology with three treatment arms, including a…
- Trial name
- NCT07150026
- Testing
- Vorinostat (SAHA)
- Where
- Colombia
- Volunteers
- 5 people
- Sponsor
- Unravel Biosciences, Inc.
Graft vs Host Disease, Hematologic Neoplasms
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
This protocol, UMCC 2012.047, was a pilot study initially intended for 12 subjects. After completing enrollment of the planned 12 subjects, we are extending the study to an additional 25 subjects.
- Conditions
- Graft vs Host Disease, Hematologic Neoplasms, Non-Neoplastic Hematologic and Lymphocytic Disorder
- Trial name
- NCT01790568
- Testing
- Vorinostat, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the highest safe dose of vorinostat that can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk MDS.
- Trial name
- NCT00656617
- Testing
- Idarubicin, Cytarabine, Vorinostat
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well vorinostat works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00238303
- Testing
- vorinostat, conventional surgery
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This phase I/II trial studies the side effects and best dose of vorinostat when given together with temozolomide and radiation therapy and to see how well they work in treating patients with newly diagnosed glioblastoma…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00731731
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cognitive Assessment, Laboratory Biomarker Analysis
- Where
- 110 sites in United States
- Volunteers
- 125 people
- Sponsor
- National Cancer Institute (NCI)
Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
This study will test the safety and effectiveness of adding bortezomib and vorinostat to other chemotherapy drugs commonly used to treat relapsed or refractory leukemia.
- Conditions
- Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT02419755
- Testing
- Bortezomib, Vorinostat, Mitoxantrone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoma, T-Cell, Cutaneous
Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
In an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported…
- Trial name
- NCT00419367
- Testing
- Comparator: vorinostat
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00703664
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma in Relapse
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)
Primary objective of the study is the determination of the maximum tolerated dose (MTD) of Vorinostat (V), given in combination with fixed doses of Doxorubicin (D), Bortezomib (B) and Dexamethasone (D).
- Trial name
- VBDD (NCT01394354)
- Testing
- Vorinostat, Bortezomib, Doxorubicin
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- University Hospital Freiburg
Lymphoma
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients…
- Trial name
- NCT00127101
- Testing
- vorinostat, Comparator: bexarotene
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuroblastoma
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat.
- Trial name
- NCT07261241
- Testing
- Radiation: 131I-MIBG, Dinutuximab, Vorinostat
- Where
- 13 sites in United States
- Volunteers
- 118 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Pruritus
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study
Mycosis Fungoides (MF) is a rare malignancy in the United States. It is the most common form of cutaneous T-cell lymphoma (CTCL). Sézary syndrome (SS) is the most severe and leukemic form of CTCL.
- Trial name
- NCT01801670
- Testing
- Biopsy, Blood
- Where
- United States
- Sponsor
- Boston University
Myelodysplastic Syndromes
Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia
The purpose of this study is to determine the maximum tolerated duration and schedule of oral VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High risk myelodysplastic syndromes.
- Trial name
- GFMVOR2007 (NCT00776503)
- Testing
- VORINOSTAT
- Where
- 14 sites in France
- Volunteers
- 52 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Sarcoma
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
This is a Phase Ib/II experimental, open-label, dose escalation, active treatment study designed to determine the safety, tolerability, and recommended dose of the combination.
- Trial name
- GemTax (NCT01879085)
- Testing
- Docetaxel, Gemcitabine, Vorinostat
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Melissa Burgess, MD
Lymphoma
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat…
- Trial name
- NCT00787527
- Testing
- Zolinza (vorinostat), Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancer
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or…
- Trial name
- NCT00907738
- Testing
- vorinostat
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01789255
- Testing
- vorinostat, tacrolimus, cyclosporine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)